, Singapore
Photo by Adrien Olichon via Pexels

Pharmesis to acquire remaining 19% stake in Sichuan Longlife Pharmaceutical

This agreement was finalised on 23 September.

Pharmesis International Ltd. has announced that its wholly-owned subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd., has signed a conditional sale and purchase agreement to acquire the remaining 19% equity interest in Sichuan Longlife Pharmaceutical Co., Ltd.

This agreement was finalised on 23 September.

The equity interest will be acquired from Chengdu Kinna Investment Co., Ltd., under the terms and conditions outlined in the SPA. 

The acquisition is part of Pharmesis International's strategic efforts to enhance its portfolio and strengthen its position in the pharmaceutical industry.

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!